May block bronchodilatory effects and produce severe bronchospasm in asthmatic patients. Patients with asthma should not normally be treated with beta-blockers.
Source: NLP:levalbuterol
Brand names: Levalbuterol
Route: Respiratory (Inhalation)
FDA Black Box Warning
For Oral Inhalation Only Levalbuterol Inhalation Solution is only for use with a nebulizer. Instructions for Using Levalbuterol Inhalation Solution
Contraindications
4 CONTRAINDICATIONS Levalbuterol inhalation solution is contraindicated in patients with a history of hypersensitivity to levalbuterol or racemic albuterol. Reactions have included urticaria, angioedema, rash, bronchospasm, anaphylaxis, and oropharyngeal edema [see Warnings and Precautions ( 5.6 ) ]. • Hypersensitivity to levalbuterol or racemic albuterol. ( 4 )
Pregnancy & Breastfeeding
8.1 Pregnancy Teratogenic Effects Pregnancy Category C There are no adequate and well-controlled studies of levalbuterol inhalation solution in pregnant women. Because animal reproduction studies are not always predictive of human response, levalbuterol inhalation solution should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. During worldwide marketing experience, various congenital anomalies, including cleft palate and limb defects, have been reported in newborns of women treated with racemic albuterol which contains the levalbuterol isomer (active drug substance of levalbuterol inhalation solution). However, since multiple medications were taken during some of the pregnancies and there was no consistent pattern of anomalies, it was not possible to establish a relationship between racemic albuterol use and the occurrence of these congenital anomalies. In animal studies, oral administration of levalbuterol HCl to pregnant New Zealand White rabbits found no evidence of teratogenicity at doses up to 25 mg/kg/day (approximately 108 times the maximum recommended daily inhalation [MRDI] dose of levalbuterol HCl for adults on a mg/m 2 basis). However, other studies demonstrated that racemic albuterol sulfate was teratogenic in mice and rabbits at doses comparable to the human therapeutic range. Pregnant mice administered racemic albuterol sulfate subcutaneously had a dose-related increased incidence of cleft palate in their fetuses (4.5% of fetuses at 0.25 mg/kg/day or greater, corresponding to approximately 0.3 times the MRDI dose, 9.3% of fetuses at 2.5 mg/kg/day, approximately 3 times the MRDI dose of levalbuterol HCl for adults on a mg/m 2 basis). The drug did not induce cleft palate formation when administered subcutaneously at a dose of 0.025 mg/kg/day (approximately 0.03 times the MRDI dose of levalbuterol HCl for adults on a mg/m 2 basis). In addition, oral administration of racemic albuterol sulfate to pregnant r
7 interactions on record
May block bronchodilatory effects and produce severe bronchospasm in asthmatic patients. Patients with asthma should not normally be treated with beta-blockers.
Source: NLP:levalbuterol
Levalbuterol should be administered with extreme caution to patients being treated with MAOIs or within 2 weeks of discontinuation due to risk of potentiating cardiovascular effects.
Source: NLP:levalbuterol
May worsen ECG changes or hypokalemia. Monitor potassium levels during coadministration.
Source: NLP:levalbuterol
Levalbuterol may decrease serum digoxin levels by 16-22%. Careful evaluation of digoxin levels is prudent in patients receiving both drugs chronically.
Source: NLP:levalbuterol
Non-potassium-sparing diuretics may worsen ECG changes or hypokalemia when combined with beta-agonists, especially at higher doses. Consider monitoring potassium levels.
Source: NLP:levalbuterol
Concomitant use with other short-acting sympathomimetic bronchodilators or epinephrine may potentiate effects and cause deleterious cardiovascular effects.
Source: NLP:levalbuterol
May worsen ECG changes or hypokalemia. Monitor potassium levels during coadministration.
Source: NLP:levalbuterol